Core Insights - PacBio has partnered with Basecamp Research to utilize its HiFi sequencing technology on the Revio system for the Trillion Gene Atlas initiative, aiming to generate a vast metagenomic dataset from approximately 100,000 samples across 31 countries and 5 continents [1][4] Group 1: Collaboration and Project Scope - The collaboration with Basecamp Research is expected to create the largest and most diverse high-fidelity metagenomic dataset to date, enhancing the understanding of evolutionary genetic diversity [1][4] - The Trillion Gene Atlas aims to expand known evolutionary genetic diversity by 100-fold, leveraging PacBio's sequencing technology to capture essential genomic structures [4][6] Group 2: Technology and Methodology - PacBio's HiFi sequencing combines high accuracy with long reads, enabling the resolution of complex genomes and microbial communities, which is crucial for metagenomic studies [3][6] - The SPRQ-Nx chemistry enhances sequencing efficiency and cost-effectiveness, making large-scale metagenomic projects more economically viable [3][4] Group 3: AI and Biological Insights - The EDEN model developed by Basecamp Research utilizes large-scale evolutionary metagenomic data to improve AI model performance, capturing biological signals that are often absent in curated reference genomes [2] - The collaboration aims to enable a new generation of AI systems capable of designing transformative medicines by integrating high-fidelity sequencing with advanced computational models [4][9]

Core Insights - Metagenomi, Inc. has appointed Dr. Laurence Reid to its Board of Directors, bringing 30 years of experience in building biotech companies and shaping business strategies [1][2] - Dr. Reid's expertise is expected to enhance Metagenomi's efforts in advancing its proprietary gene editing technologies and developing curative genetic medicines [2] Company Overview - Metagenomi is a precision gene editing company utilizing artificial intelligence and machine learning to create potentially curative genome editing therapeutics [3] - The company’s gene editing toolbox has analyzed over 7.4 billion proteins, enabling it to target various genetic mutations across the human genome [3] - Metagenomi's lead program focuses on Hemophilia A, aiming to provide lifelong protection from bleeding events and joint damage [3] Leadership Background - Dr. Reid has a strong track record as a biotech executive, having served in leadership roles at several companies, including Decibel Therapeutics and Warp Drive Bio [2] - He is currently the chairperson of Broken String Biosciences and serves on the boards of KalVista Pharmaceuticals and other private biotech firms [2] - Dr. Reid holds a B.A. in natural sciences from Cambridge University and a Ph.D. in biochemistry from King's College, London University [2]

Company Vision and Strategy - Metagenomi's vision is to harness its metagenomics platform to create curative genetic medicines for patients[8] - The company's strategy involves using a diverse and modular genome editing toolbox to precisely target any site in the human genome, addressing the full spectrum of genetic diseases[9] - Metagenomi focuses on investments in development and manufacturing across gene editing technologies to enable rapid advancement to the clinic[11] Disease Targets and Pipeline - Hundreds of millions of people worldwide have diseases potentially treatable with gene editing, including over 180 million with rare diseases of genetic origin and over 200 million with cardiovascular disease tied to genetic risk factors[14] - The company's pipeline includes programs targeting Hemophilia A (affecting more than 500,000 patients globally), Transthyretin Amyloidosis (TTR) (affecting 300,000–500,000 patients globally), and Refractory Hypertension (affecting 900,000 patients in the US)[14, 19] - Metagenomi's Hemophilia A program, MGX-001, has demonstrated sustained Factor VIII activity in non-human primate (NHP) studies for more than 16 months[53] Technology and Platform - Metagenomi's metagenomics platform is the foundation of its gene editing toolbox, involving proprietary sampling, AI-powered screening, and engineering & optimization[20, 22, 24, 25] - The company has a proprietary library of highly precise and efficient nucleases, including ultra-small systems (SMARTs), providing a programmable chassis for other gene editing tools[31] - Metagenomi's base editing platform achieves efficient multiplex editing for cell engineering, with reprogrammed chassis increasing genome targetability[112, 113] Partnerships and Corporate Overview - Metagenomi has strategic collaborations, including one with Ionis focusing on cardiometabolic diseases, with up to 8 targets and potential milestone payments and royalties up to $2.9 billion[50] - The company is well-capitalized with a cash runway into 2027[135]

Table of Contents As filed with the Securities and Exchange Commission on February 7, 2024. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Metagenomi, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 83-2735153 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) Metagenomi ...

Table of Contents As filed with the Securities and Exchange Commission on February 5, 2024. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO Delaware 2836 83-2735153 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) Metagenomi, Inc. 5959 Horton Street, 7th Floor Emeryville, California 94608 (510) 871-4880 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) B ...

Table of Contents As filed with the Securities and Exchange Commission on January 8, 2024. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Metagenomi Technologies, LLC (to be succeeded by Metagenomi, Inc. in the reorganization) (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) D ...

Table of Contents As filed with the Securities and Exchange Commission on January 5, 2024. Registration No. 333– UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Metagenomi Technologies, LLC (to be succeeded by Metagenomi, Inc. in the reorganization) (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 83-2735153 (Primary Standard Industrial C ...